Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report

Clin Exp Rheumatol. 2007 Sep-Oct;25(5):758-9.

Abstract

Interleukin 1 (IL1) plays an important role in adult onset Still's disease. Anakinra (Kineret), a recombinant IL1 Receptor Antagonist (IL 1 RA) was therefore recently proposed in adult onset Still's disease with great efficacy. Anakinra appeared to be well tolerated and safe. The case of a patient with refractory adult onset Still's disease who experienced a Systemic Inflammatory Response Syndrome and Adult Respiratory Distress Syndrome requiring intensive care unit hospitalization 10 days after the introduction of anakinra is reported.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / adverse effects*
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Interleukin-1 / antagonists & inhibitors
  • Interleukin-1 / physiology
  • Male
  • Respiratory Distress Syndrome / chemically induced
  • Still's Disease, Adult-Onset / drug therapy*
  • Still's Disease, Adult-Onset / physiopathology
  • Systemic Inflammatory Response Syndrome / chemically induced*
  • Systemic Inflammatory Response Syndrome / diagnosis

Substances

  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1